Sodium signal intensity of CSF using 1H-guided 23Na-MRI as a potential noninvasive biomarker in Alzheimer's disease.
Alzheimer's disease
biomarkers
cerebrospinal fluid (CSF)
magnetic resonance imaging
sodium (23Na) MRI
Journal
Journal of neuroimaging : official journal of the American Society of Neuroimaging
ISSN: 1552-6569
Titre abrégé: J Neuroimaging
Pays: United States
ID NLM: 9102705
Informations de publication
Date de publication:
28 May 2024
28 May 2024
Historique:
revised:
14
05
2024
received:
10
01
2024
accepted:
14
05
2024
medline:
29
5
2024
pubmed:
29
5
2024
entrez:
29
5
2024
Statut:
aheadofprint
Résumé
Alzheimer's disease (AD) is characterized by cognitive decline and mnestic deficits. The pathophysiology of AD is not fully understood, which renders the development of accurate tools for early diagnosis and effective therapies exceedingly difficult. In this study, we investigated the use of We prospectively recruited 11 patients with biomarker-diagnosed early-stage AD, as well as 12 cognitively healthy age-matched controls. All participants underwent RSSIs in CSF were significantly higher in AD patients (mean = 68.6% ± 7.7%) compared to healthy controls (mean = 56.9% ± 5.5%) (p < .001). There was also a significant negative correlation between rSSI in CSF and hippocampus and amygdala volumes (r = -.54 and -.49, p < .05) as well as a positive correlation with total CSF volumes (r = .81, p < .05). Receiver operating characteristic analysis showed high diagnostic accuracy for rSSI in discriminating between AD patients and healthy controls (area under the curve = .94). Our study provides evidence that rSSI in CSF is increased in AD patients in comparison to healthy controls. rSSI may serve as a potential marker for early detection and monitoring of disease progression. Larger, longitudinal studies are needed to confirm our findings and to investigate the association between rSSI in CSF and the severity of cognitive impairment.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Alzheimer's disease (AD) is characterized by cognitive decline and mnestic deficits. The pathophysiology of AD is not fully understood, which renders the development of accurate tools for early diagnosis and effective therapies exceedingly difficult. In this study, we investigated the use of
METHODS
METHODS
We prospectively recruited 11 patients with biomarker-diagnosed early-stage AD, as well as 12 cognitively healthy age-matched controls. All participants underwent
RESULTS
RESULTS
RSSIs in CSF were significantly higher in AD patients (mean = 68.6% ± 7.7%) compared to healthy controls (mean = 56.9% ± 5.5%) (p < .001). There was also a significant negative correlation between rSSI in CSF and hippocampus and amygdala volumes (r = -.54 and -.49, p < .05) as well as a positive correlation with total CSF volumes (r = .81, p < .05). Receiver operating characteristic analysis showed high diagnostic accuracy for rSSI in discriminating between AD patients and healthy controls (area under the curve = .94).
CONCLUSION
CONCLUSIONS
Our study provides evidence that rSSI in CSF is increased in AD patients in comparison to healthy controls. rSSI may serve as a potential marker for early detection and monitoring of disease progression. Larger, longitudinal studies are needed to confirm our findings and to investigate the association between rSSI in CSF and the severity of cognitive impairment.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : None
Informations de copyright
© 2024 The Author(s). Journal of Neuroimaging published by Wiley Periodicals LLC on behalf of American Society of Neuroimaging.
Références
Vitvitsky VM, Garg SK, Keep RF, et al. Na+ and K+ ion imbalances in Alzheimer's disease. Biochim Biophys Acta. 2012;1822:1671–1681.
Ge M, Zhang J, Chen S, et al. Role of calcium homeostasis in Alzheimer's disease. Neuropsychiatr Dis Treat. 2022;18:487–498.
Tampi RR, Forester BP, Agronin M. Aducanumab: evidence from clinical trial data and controversies. Drugs Contex. 2021;10:2021‐7‐3.
Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild‐to‐moderate Alzheimer's disease. N Engl J Med. 2014;370:322–333.
Boers AM, Jansen IG, Berkhemer OA, et al. Collateral status and tissue outcome after intra‐arterial therapy for patients with acute ischemic stroke. J Cereb Blood Flow Metab. 2017;37:3589–3598.
Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016;8:595–608.
Hampel H, Hardy J, Blennow K, et al. The amyloid‐beta pathway in Alzheimer's disease. Mol Psychiatry. 2021;26:5481–5503.
Budd Haeberlein S, Aisen PS, Barkhof F, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer's disease. J Prev Alzheimers Dis. 2022;9:197–210.
van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023;388:9–21.
Larkin HD. Lecanemab gains FDA approval for early Alzheimer disease. JAMA. 2023;329:363.
Avgerinos KI, Ferrucci L, Kapogiannis D. Effects of monoclonal antibodies against amyloid‐beta on clinical and biomarker outcomes and adverse event risks: a systematic review and meta‐analysis of phase III RCTs in Alzheimer's disease. Ageing Res Rev. 2021;68:101339.
Zetterberg H, Bendlin BB. Biomarkers for Alzheimer's disease‐preparing for a new era of disease‐modifying therapies. Mol Psychiatry. 2021;26:296–308.
Kehoe EG, McNulty JP, Mullins PG, et al. Advances in MRI biomarkers for the diagnosis of Alzheimer's disease. Biomark Med. 2014;8:1151–1169.
Hameed S, Fuh JL, Senanarong V, et al. Role of fluid biomarkers and PET imaging in early diagnosis and its clinical implication in the management of Alzheimer's disease. J Alzheimers Dis Rep. 2020;4:21–37.
Chang CH, Lin CH, Lane HY. Machine learning and novel biomarkers for the diagnosis of Alzheimer's disease. Int J Mol Sci. 2021;22:2761.
Neumaier‐Probst E, Konstandin S, Ssozi J, et al. A double‐tuned (1) H/(23) Na resonator allows (1) H‐guided (23) Na‐MRI in ischemic stroke patients in one session. Int J Stroke. 2015;10(Suppl A100):56–61.
Eisele P, Konstandin S, Szabo K, et al. Temporal evolution of acute multiple sclerosis lesions on serial sodium ((23)Na) MRI. Mult Scler Relat Disord. 2019;29:48–54.
Ouwerkerk R, Bleich KB, Gillen JS, et al. Tissue sodium concentration in human brain tumors as measured with 23Na MR imaging. Radiology. 2003;227:529–537.
Mohamed SA, Herrmann K, Adlung A, et al. Evaluation of sodium ((23)Na) MR‐imaging as a biomarker and predictor for neurodegenerative changes in patients with Alzheimer's disease. In Vivo. 2021;35:429–435.
Graham SF, Nasarauddin MB, Carey M, et al. Quantitative measurement of [Na+] and [K+] in postmortem human brain tissue indicates disturbances in subjects with Alzheimer's disease and dementia with Lewy bodies. J Alzheimers Dis. 2015;44:851–857.
Haeger A, Bottlaender M, Lagarde J, et al. What can 7T sodium MRI tell us about cellular energy depletion and neurotransmission in Alzheimer's disease? Alzheimers Dement. 2021;17:1843–1854.
Nation DA, Sweeney MD, Montagne A, et al. Blood‐brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med. 2019;25:270–276.
Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183–194.
Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303–308.
Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment–beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004;256:240–246.
Morris JC, Mohs RC, Rogers H, et al. Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. Psychopharmacol Bull. 1988;24:641–652.
Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:270–279.
Vanderstichele H, Bibl M, Engelborghs S, et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement. 2012;8:65–73.
McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263–269.
Nagel AM, Laun FB, Weber MA, et al. Sodium MRI using a density‐adapted 3D radial acquisition technique. Magn Reson Med. 2009;62:1565–1573.
Mellon EA, Pilkinton DT, Clark CM, et al. Sodium MR imaging detection of mild Alzheimer disease: preliminary study. AJNR Am J Neuroradiol. 2009;30:978–984.
Korf ES, Wahlund LO, Visser PJ, et al. Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. Neurology. 2004;63:94–100.
Babić Leko M, Jurasović J, Nikolac Perković M, et al. The association of essential metals with APOE genotype in Alzheimer's disease. J Alzheimers Dis. 2021;82:661–672.
Babic Leko M, Mihelcic M, Jurasovic J, et al. Heavy metals and essential metals are associated with cerebrospinal fluid biomarkers of Alzheimer's disease. Int J Mol Sci. 2022;24:467.
Noble W, Hanger DP, Miller CC, et al. The importance of tau phosphorylation for neurodegenerative diseases. Front Neurol. 2013;4:83.
Alonso AD, Cohen LS, Corbo C, et al. Hyperphosphorylation of tau associates with changes in its function beyond microtubule stability. Front Cell Neurosci. 2018;12:338.
Chalbot S, Zetterberg H, Blennow K, et al. Blood‐cerebrospinal fluid barrier permeability in Alzheimer's disease. J Alzheimers Dis. 2011;25:505–515.
Ott BR, Jones RN, Daiello LA, et al. Blood‐cerebrospinal fluid barrier gradients in mild cognitive impairment and Alzheimer's disease: relationship to inflammatory cytokines and chemokines. Front Aging Neurosci. 2018;10:245.
Ding D, Wang X, Li Q, et al. Research on the glial‐lymphatic system and its relationship with Alzheimer's disease. Front Neurosci. 2021;15:605586.
Souza LAC, Trebak F, Kumar V, et al. Elevated cerebrospinal fluid sodium in hypertensive human subjects with a family history of Alzheimer's disease. Physiol Genomics. 2020;52:133–142.
Urbanits S. Cellular diagnostics of CSF. Ejifcc. 2004;15:51–53.
Adlung A, Licht C, Reichert S, et al. Quantification of tissue sodium concentration in the ischemic stroke: a comparison between external and internal references for (23)Na MRI. J Neurosci Methods. 2022;382:109721.
Hussain A, Sheikh Z, Subramanian M. The eye as a diagnostic tool for Alzheimer's disease. Life. 2023;13:726.
Vig V, Garg I, Tuz‐Zahra F et al. Vitreous humor biomarkers reflect pathological changes in the brain for Alzheimer's disease and chronic traumatic encephalopathy. J Alzheimers Dis. 2023;93:1181–1193.